# Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

> **NCT00171951** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Cushing Disease

## Interventions

- **DRUG:** Pasireotide

## Key facts

- **NCT ID:** NCT00171951
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08-13
- **Primary completion:** 2013-07-08
- **Final completion:** 2013-07-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171951, "Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00171951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*